{"id":"serd","rwe":[{"pmid":"41752108","year":"2026","title":"A Systematic Review of Major Advances in Breast Cancer Therapeutics in 2025: Synthesis of Conference and Published Evidence.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"41700494","year":"2026","title":"Selective Estrogen Receptor Modulators (SERMs): Advances, Challenges, and Future Prospects in ER+ Breast Cancer Therapy.","finding":"","journal":"Archiv der Pharmazie","studyType":"Clinical Study"},{"pmid":"41681834","year":"2026","title":"A Decade of Innovation in Breast Cancer (2015-2025): A Comprehensive Review of Clinical Trials, Targeted Therapies and Molecular Perspectives.","finding":"","journal":"Cancers","studyType":"Clinical Study"},{"pmid":"41678931","year":"2026","title":"Treatment of ER-positive breast cancer with FDA-approved aromatase inhibitors.","finding":"","journal":"Cancer treatment and research communications","studyType":"Clinical Study"},{"pmid":"41570399","year":"2026","title":"Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1.","finding":"","journal":"ESMO open","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Fudan University","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Decreased appetite","drugRate":"","severity":"common","organSystem":""},{"effect":"Insomnia","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Weight decreased","drugRate":"","severity":"common","organSystem":""},{"effect":"Anxiety","drugRate":"","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Irritability","drugRate":"","severity":"common","organSystem":""},{"effect":"Affect lability","drugRate":"","severity":"common","organSystem":""},{"effect":"Tachycardia","drugRate":"","severity":"common","organSystem":""},{"effect":"Blood pressure increased","drugRate":"","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Pancytopenia","drugRate":"","severity":"serious"},{"effect":"Thrombocytopenia","drugRate":"","severity":"serious"},{"effect":"Thrombocytopenic purpura","drugRate":"","severity":"serious"},{"effect":"Angina pectoris","drugRate":"","severity":"serious"},{"effect":"Bradycardia","drugRate":"","severity":"serious"}]},"trials":[],"aliases":["Elacestrant"],"company":"Fudan University","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=SERD","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:55:46.206807+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T05:55:58.645970+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:55:51.340332+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SERD","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:55:51.704650+00:00"}},"allNames":["serd"],"offLabel":[],"synonyms":[],"timeline":[],"aiSummary":"Serd, developed by Fudan University, is a marketed small molecule for the treatment of attention deficit hyperactivity disorder (ADHD). The drug's key strength lies in its unique mechanism of action, which interacts with specific biological pathways to produce a therapeutic effect. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.","approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Serd is a small molecule that likely acts as a ligand to bind to a specific receptor or enzyme, triggering a downstream signaling cascade that produces its therapeutic effect."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=serd","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=serd","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:22:46.774798","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:55:58.646067+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"serd","indications":{"approved":[{"name":"Attention deficit hyperactivity disorder","diseaseId":"attention-deficit-hyperactivity-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05573126","phase":"PHASE1,PHASE2","title":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","status":"RECRUITING","sponsor":"Ellipses Pharma","startDate":"2023-01-11","conditions":["Hormone Receptor-positive Breast Cancer","Hormone Receptor Positive HER-2 Negative Breast Cancer","Metastatic Breast Cancer"],"enrollment":95,"completionDate":"2028-02"},{"nctId":"NCT07340541","phase":"PHASE2","title":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-02","conditions":["Breast Cancer","Metastatic Breast Cancer","Triple Negative Breast Cancer","Estrogen-receptor-positive Breast Cancer","Hormone Receptor Negative Breast Carcinoma"],"enrollment":700,"completionDate":"2031-06-02"},{"nctId":"NCT05659563","phase":"PHASE2","title":"Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%","status":"COMPLETED","sponsor":"MedSIR","startDate":"2023-07-20","conditions":["Breast Cancer","Breast Cancer, Early-Onset"],"enrollment":92,"completionDate":"2025-01-30"},{"nctId":"NCT06075953","phase":"PHASE2","title":"DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2024-02-17","conditions":["Ductal Carcinoma in Situ"],"enrollment":400,"completionDate":"2033-11"},{"nctId":"NCT07085767","phase":"PHASE3","title":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","startDate":"2025-11-03","conditions":["Breast Cancer","Locally Advanced Breast Cancer","Metastatic Breast Cancer","ER Positive Breast Cancer","HER2 Negative Breast Carcinoma"],"enrollment":1000,"completionDate":"2032-01"},{"nctId":"NCT06382948","phase":"PHASE3","title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-12-05","conditions":["Advanced Breast Cancer","ER-positive Breast Cancer","HER2-negative Breast Cancer","ESR1 Gene Mutation"],"enrollment":240,"completionDate":"2028-04"},{"nctId":"NCT06380751","phase":"PHASE3","title":"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-01","conditions":["Advanced Breast Cancer"],"enrollment":500,"completionDate":"2030-10-18"},{"nctId":"NCT07467772","phase":"PHASE2","title":"Ph 2 Elacestrant in ER Positive Uterine Sarcomas","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-02","conditions":["Uterine Sarcoma","Uterine Leiomyosarcoma","Endometrial Stromal Sarcoma","ESS","Perivascular Epithelioid Cell Tumors","Uterine Adenosarcoma","Uterine PEComa","Estrogen Receptor Positive Tumor","uLMS"],"enrollment":30,"completionDate":"2028-04"},{"nctId":"NCT06065748","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-12-11","conditions":["Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer"],"enrollment":1050,"completionDate":"2029-02-12"},{"nctId":"NCT05708235","phase":"PHASE2","title":"A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-04-01","conditions":["Breast Cancer"],"enrollment":976,"completionDate":"2028-06-30"},{"nctId":"NCT05774951","phase":"PHASE3","title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-31","conditions":["Breast Cancer, Early Breast Cancer"],"enrollment":4300,"completionDate":"2036-05-29"},{"nctId":"NCT07408089","phase":"PHASE1","title":"Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Boundless Bio, Inc.","startDate":"2026-02-25","conditions":["Breast Cancer","Metastatic Breast Cancer","Advanced Breast Cancer"],"enrollment":96,"completionDate":"2029-05-31"},{"nctId":"NCT06188520","phase":"PHASE1,PHASE2","title":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-05","conditions":["ER+ HER2- Advanced Breast Cancer","High-grade Serous Ovarian Cancer (HGSOC)"],"enrollment":564,"completionDate":"2027-08-04"},{"nctId":"NCT07427394","phase":"PHASE2","title":"Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-04-10","conditions":["Advanced Breast Cancer"],"enrollment":24,"completionDate":"2027-12-03"},{"nctId":"NCT04644068","phase":"PHASE1,PHASE2","title":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-11-12","conditions":["Ovarian Cancer","Breast Cancer","Pancreatic Cancer","Prostate Cancer","Additional Indications Below for Module 4 and 5","Non-small Cell Lung Cancer","Colorectal Cancer","Bladder Cancer","Gastric Cancer","Biliary Cancer","Cervical Cancer","Endometrial Cancer","Small Cell Lung Cancer Only in Module 5"],"enrollment":702,"completionDate":"2027-05-28"},{"nctId":"NCT05696184","phase":"NA","title":"Mechanisms Preventing Pharyngeal Reflux","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2013-11-01","conditions":["GERD"],"enrollment":300,"completionDate":"2026-10-12"},{"nctId":"NCT07222215","phase":"PHASE2","title":"PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)","status":"RECRUITING","sponsor":"Kristina A. Fanucci","startDate":"2026-01-16","conditions":["Estrogen-receptor-positive Breast Cancer","Metastatic Breast Cancer","Breast Cancer","Hormone Receptor Positive Breast Cancer","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","HER2- Breast Cancer","ESR1 Gene Mutation","ER Wildtype","Breast Neoplasms"],"enrollment":297,"completionDate":"2030-10-01"},{"nctId":"NCT04692103","phase":"PHASE2","title":"Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-07-10","conditions":["Estrogen Receptor Positive","Primary or Recurrent Breast Carcinoma","Stage IV Breast Cancer AJCC v6 and v7"],"enrollment":2,"completionDate":"2041-04-30"},{"nctId":"NCT04964934","phase":"PHASE3","title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-30","conditions":["ER-Positive HER2-Negative Breast Cancer"],"enrollment":315,"completionDate":"2027-11-26"},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":["Breast Cancer","ER-positive Breast Cancer","HER2-negative Breast Cancer","Metastatic Breast Cancer"],"enrollment":24,"completionDate":"2029-07-31"},{"nctId":"NCT07235176","phase":"PHASE1,PHASE2","title":"Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-01-05","conditions":["Advanced ER+/HER2- Breast Cancer"],"enrollment":300,"completionDate":"2031-12-30"},{"nctId":"NCT07318805","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-12-16","conditions":["Advanced Breast Cancer","Metastatic Breast Cancer (HR+/ HER2-)","Colorectal Cancer","Metastatic Colorectal Adenocarcinoma","Triple Negative Breast Cancer"],"enrollment":260,"completionDate":"2030-04-14"},{"nctId":"NCT06201234","phase":"PHASE2","title":"Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"GBG Forschungs GmbH","startDate":"2024-12-13","conditions":["Hormone Receptor Positive HER-2 Negative Breast Cancer","Advanced or Metastatic Breast Cancer","BRCA1 Mutation","BRCA2 Mutation"],"enrollment":176,"completionDate":"2028-12-31"},{"nctId":"NCT04214288","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-04-22","conditions":["Advanced ER-Positive HER2-Negative Breast Cancer"],"enrollment":240,"completionDate":"2026-03-17"},{"nctId":"NCT07180160","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer","status":"RECRUITING","sponsor":"Wenjin Yin","startDate":"2025-09-25","conditions":["Advanced Breast Cancer"],"enrollment":123,"completionDate":"2028-03"},{"nctId":"NCT03079011","phase":"PHASE3","title":"PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2017-03-22","conditions":["Metastatic Breast Cancer"],"enrollment":1017,"completionDate":"2025-09-22"},{"nctId":"NCT04647487","phase":"PHASE1","title":"A Study of LY3484356 in Women With Breast Cancer Before Having Surgery","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-04-21","conditions":["Breast Cancer"],"enrollment":87,"completionDate":"2022-11-11"},{"nctId":"NCT07191717","phase":"PHASE2","title":"Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial","status":"NOT_YET_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2026-04-30","conditions":["Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Invasive Breast Carcinoma","Localized Estrogen Receptor-Positive Breast Carcinoma","Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma"],"enrollment":42,"completionDate":"2031-04-30"},{"nctId":"NCT07198724","phase":"PHASE1,PHASE2","title":"ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sarah Sammons, MD","startDate":"2026-03","conditions":["Metastatic Breast Cancer","HER2 Low Breast Carcinoma","HER2-negative Breast Cancer","Breast Cancer","Breast Cancer Female"],"enrollment":65,"completionDate":"2038-06-01"},{"nctId":"NCT04711252","phase":"PHASE3","title":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-01-28","conditions":["ER-Positive HER2-Negative Breast Cancer"],"enrollment":1370,"completionDate":"2029-02-01"},{"nctId":"NCT06784193","phase":"PHASE1","title":"Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","startDate":"2024-12-16","conditions":["Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)","Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)","Metastatic Breast Cancer","Fulvestrant","Palazestrant"],"enrollment":180,"completionDate":"2027-08-30"},{"nctId":"NCT07195227","phase":"PHASE2","title":"Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2025-12-01","conditions":["Hormon Receptor Positive Breast Cancer","Breast Cancer"],"enrollment":150,"completionDate":"2028-03"},{"nctId":"NCT03425838","phase":"PHASE3","title":"Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Borstkanker Onderzoek Groep","startDate":"2017-11-09","conditions":["Breast Neoplasm Female"],"enrollment":1050,"completionDate":"2025-12"},{"nctId":"NCT04191382","phase":"PHASE2","title":"Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2020-02-04","conditions":["Breast Cancer"],"enrollment":105,"completionDate":"2021-05-28"},{"nctId":"NCT07163481","phase":"PHASE1","title":"A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Hunan Cancer Hospital","startDate":"2025-10","conditions":["Stage IV (Metastatic) Breast Cancer"],"enrollment":12,"completionDate":"2026-12"},{"nctId":"NCT06000501","phase":"PHASE4","title":"Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2023-11-13","conditions":["Adult Attention Deficit Hyperactivity Disorder"],"enrollment":29,"completionDate":"2024-07-17"},{"nctId":"NCT04975308","phase":"PHASE3","title":"A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2021-10-04","conditions":["Breast Neoplasms","Neoplasm Metastasis"],"enrollment":874,"completionDate":"2027-08"},{"nctId":"NCT05952557","phase":"PHASE3","title":"An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-10-05","conditions":["Breast Cancer, Early Breast Cancer"],"enrollment":5500,"completionDate":"2037-05-06"},{"nctId":"NCT05304962","phase":"PHASE1","title":"FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Regor Pharmaceuticals Inc.","startDate":"2022-03-04","conditions":["Breast Cancer"],"enrollment":64,"completionDate":"2026-09-30"},{"nctId":"NCT06882499","phase":"NA","title":"Stereotactic Ablative Body Radiotherapy (SABR) with Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II","status":"NOT_YET_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2025-05-01","conditions":["Breast Cancer, Metastatic","Metastatic Breast Cancer"],"enrollment":74,"completionDate":"2032-02"},{"nctId":"NCT05293964","phase":"PHASE1","title":"Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2022-05-18","conditions":["Breast Cancer"],"enrollment":214,"completionDate":"2025-09-08"},{"nctId":"NCT03560531","phase":"PHASE1,PHASE2","title":"A Study of ZN-c5 in Subjects With Breast Cancer","status":"COMPLETED","sponsor":"Zeno Alpha Inc.","startDate":"2018-11-30","conditions":["Breast Cancer"],"enrollment":181,"completionDate":"2022-12-22"},{"nctId":"NCT05720260","phase":"PHASE2","title":"Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2023-01-17","conditions":["Premenopausal Breast Cancer","Metastatic Breast Cancer","ER Positive Breast Cancer"],"enrollment":42,"completionDate":"2027-01-31"},{"nctId":"NCT05205200","phase":"PHASE2","title":"Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-06-06","conditions":["Breast Cancer","Metastatic Cancer"],"enrollment":338,"completionDate":"2026-08-01"},{"nctId":"NCT04869943","phase":"PHASE3","title":"Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Veru Inc.","startDate":"2021-10-12","conditions":["Metastatic Breast Cancer"],"enrollment":52,"completionDate":"2024-01-09"},{"nctId":"NCT04514159","phase":"PHASE1","title":"A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer","status":"COMPLETED","sponsor":"Zeno Alpha Inc.","startDate":"2020-11-12","conditions":["Breast Cancer"],"enrollment":14,"completionDate":"2022-10-24"},{"nctId":"NCT05551897","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-10-04","conditions":["Healthy Subjects"],"enrollment":14,"completionDate":"2022-12-28"},{"nctId":"NCT03455270","phase":"PHASE1","title":"G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer","status":"COMPLETED","sponsor":"G1 Therapeutics, Inc.","startDate":"2018-05-09","conditions":["Carcinoma, Ductal, Breast","Breast Cancer Female","Breast Neoplasm","Breast Cancer","Metastatic Breast Cancer","Advanced Breast Cancer","Stage IV Breast Cancer"],"enrollment":107,"completionDate":"2022-09-29"},{"nctId":"NCT02650817","phase":"PHASE1","title":"Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Stemline Therapeutics, Inc.","startDate":"2016-04-01","conditions":["Metastatic Breast Cancer"],"enrollment":16,"completionDate":"2019-10-18"},{"nctId":"NCT02734615","phase":"PHASE1","title":"Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-06-14","conditions":["Advanced or Metastatic ER+ Breast Cancer"],"enrollment":199,"completionDate":"2021-09-13"},{"nctId":"NCT04355858","phase":"PHASE2","title":"Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-05-01","conditions":["Breast Cancer","Metastatic Cancer"],"enrollment":319,"completionDate":"2025-04-01"},{"nctId":"NCT02149173","phase":"NA","title":"F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy","status":"TERMINATED","sponsor":"University of Washington","startDate":"2010-09-15","conditions":["Estrogen Receptor Positive","Recurrent Breast Carcinoma","Stage IV Breast Cancer AJCC v6 and v7"],"enrollment":29,"completionDate":"2021-01-13"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Fudan University","relationship":"Original Developer"}],"publicationCount":323,"therapeuticAreas":["Other"],"biosimilarFilings":[],"originalDeveloper":"Fudan University","recentPublications":[{"date":"2026 Feb 19","pmid":"41752108","title":"A Systematic Review of Major Advances in Breast Cancer Therapeutics in 2025: Synthesis of Conference and Published Evidence.","journal":"International journal of molecular sciences"},{"date":"2026 Feb","pmid":"41700494","title":"Selective Estrogen Receptor Modulators (SERMs): Advances, Challenges, and Future Prospects in ER+ Breast Cancer Therapy.","journal":"Archiv der Pharmazie"},{"date":"2026 Jan 23","pmid":"41681834","title":"A Decade of Innovation in Breast Cancer (2015-2025): A Comprehensive Review of Clinical Trials, Targeted Therapies and Molecular Perspectives.","journal":"Cancers"},{"date":"2026 Feb 7","pmid":"41678931","title":"Treatment of ER-positive breast cancer with FDA-approved aromatase inhibitors.","journal":"Cancer treatment and research communications"},{"date":"2026 Feb","pmid":"41570399","title":"Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1.","journal":"ESMO open"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"SERD","companyName":"Fudan University","companyId":"fudan-university","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":9,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:55:58.646067+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}